Critical Analysis: Edwards Lifesciences (EW) & Its Rivals

Edwards Lifesciences (NYSE:EW – Get Free Report) is one of 510 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare Edwards Lifesciences to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Edwards Lifesciences and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences 0 3 23 0 2.88
Edwards Lifesciences Competitors 4324 10555 18357 840 2.46

Edwards Lifesciences currently has a consensus price target of $109.88, suggesting a potential upside of 7.87%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 29.07%. Given Edwards Lifesciences’ peers higher possible upside, analysts plainly believe Edwards Lifesciences has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Edwards Lifesciences and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Edwards Lifesciences $6.07 billion $1.07 billion 57.55
Edwards Lifesciences Competitors $1.87 billion $136.77 million 5.94

Edwards Lifesciences has higher revenue and earnings than its peers. Edwards Lifesciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Edwards Lifesciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Edwards Lifesciences’ peers have a beta of 2.58, suggesting that their average stock price is 158% more volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Edwards Lifesciences 15.30% 16.06% 12.36%
Edwards Lifesciences Competitors -191.34% -187.68% -21.85%

Institutional & Insider Ownership

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Edwards Lifesciences beats its peers on 9 of the 13 factors compared.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.